Orchid: Funding, Investors & Team (Sep 2026)
Orchid, a startup in the field of reproductive technology, developed a system that can identify rare genetic disorders. Through its preconception system, Orchid examines the genetic makeup of both partners and evaluates their predisposition to common diseases such as heart disease, stroke, schizophrenia, Alzheimer's disease, breast cancer, and diabetes. With the assistance of reputable experts in reproductive medicine and genetics, Orchid aims to provide its clients with highly accurate results. One of the services Orchid offers is the "Couple Report," which involves a simple saliva test done at home to analyze the genomes of each person and determine the probability of genetic risks, specifically how their DNA could potentially combine in a future child. In cases where an increased risk is identified, Orchid provides valuable insights to aid couples in monitoring biomarkers, adjusting their diet, or considering options like in vitro fertilization. Orchid was founded by Noor Siddiqui in 2019 and is headquartered in San Francisco, California.
Orchid has raised $16.5M across 2 funding rounds on record, the most recent a Seed of $12.0M announced in Dec 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Orchid Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Orchid Funding Rounds
Orchid raised $4.5M in a Seed announced in Apr 2021.
2.7 years later, a Seed of $12.0M was announced in Dec 2023.
Orchid Founders and Leadership Team
Contact details for the Orchid team: 1 of 1 has an email address on file.
Start 14-day free trial →Orchid Funding Compared to Other Biotechnology Startups
Orchid's latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Orchid in Biotechnology and San Francisco
Companies Similar to Orchid
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Orchid Funding FAQs
What does Orchid do?
Orchid, a startup in the field of reproductive technology, developed a system that can identify rare genetic disorders. Through its preconception system, Orchid examines the genetic makeup of both partners and evaluates their predisposition to common diseases such as heart disease, stroke, schizophrenia, Alzheimer's disease, breast cancer, and diabetes. With the assistance of reputable experts in reproductive medicine and genetics, Orchid aims to provide its clients with highly accurate results. One of the services Orchid offers is the "Couple Report," which involves a simple saliva test done at home to analyze the genomes of each person and determine the probability of genetic risks, specifically how their DNA could potentially combine in a future child. In cases where an increased risk is identified, Orchid provides valuable insights to aid couples in monitoring biomarkers, adjusting their diet, or considering options like in vitro fertilization. Orchid was founded by Noor Siddiqui in 2019 and is headquartered in San Francisco, California.
How much funding has Orchid raised?
Orchid has raised $16.5M across 2 rounds on record. The most recent is a Seed of $12.0M announced in Dec 2023.
When did Orchid last raise funding?
Orchid's most recent funding round on record is a Seed of $12.0M, announced in Dec 2023.
Who is the CEO of Orchid?
Noor Siddiqui is listed as CEO at Orchid.
Where is Orchid headquartered?
Orchid is based in San Francisco, California, United States.
How many employees does Orchid have?
Orchid is in the 11-50 employee band.
How does Orchid's funding compare to other Biotechnology startups?
Orchid's latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Orchid Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Orchid is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.